Female infertility. Female infertility
Conditions
Interventions
Intervention 1: Dehydroepiandrosterone pharmaceutical tablet manufacturing company Puritant`pride USA, 25 mg orally three times in 8 weeks before embryo transfer in patients undergoing IVF are given.
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: Candidates for IVF over 35 years Body mass index between 18 and 25 (kg/m^2) FSH hormone levels less than 10 IU / L
Exclusion criteria
Exclusion criteria: Systemic diseases such as diabetes, thyroid diseases History of ovarian surgery History of receiving DHEA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate. Timepoint: Fourth week after intervention. Method of measurement: Based on Beta-HCG and ultrasound confirmation.;Chemical pregnancy rate. Timepoint: The second week after the intervention. Method of measurement: Based on Beta-HCG a confirmation.;Miscarriage rates. Timepoint: Before 6 and 20 weeks after the intervention. Method of measurement: File.;Endometrial thickness before embryo transfer. Timepoint: Before embryo transfer. Method of measurement: Using ultrasound.;Duration of stimulation. Timepoint: Time required for follicle growth. Method of measurement: Using ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoghra Rabiei
Hamedan University of Medical Sciences
Outcome results
None listed